Sage Therapeutics and Biogen End Collaboration on SAGE-324 Program

Sage Therapeutics, Inc. (NASDAQ: SAGE) announced the discontinuation of its collaboration with Biogen Inc. (NASDAQ: BIIB) on the SAGE-324 program following recent negative Phase 2 trial results. Despite this, the companies will continue their partnership on ZURZUVAE®, the first FDA-approved oral treatment for postpartum depression (PPD).

Key Highlights:

• Discontinuation of SAGE-324 Program: Biogen has terminated its rights under the collaboration agreement with Sage specific to SAGE-324. This decision follows the negative results of the Phase 2 KINETIC 2 study for the treatment of essential tremor (ET).
• Effective Termination: The collaboration and license agreement will end on February 17, 2025, with Sage resuming full ownership of the SAGE-324 asset.
• Potential Future Evaluation: Sage plans to assess other potential indications for SAGE-324, if any, despite the discontinuation in ET.
• Continuing Partnership on ZURZUVAE®: Sage and Biogen will maintain their collaboration on ZURZUVAE®, continuing their efforts to support women with postpartum depression.

About Sage Therapeutics
Sage Therapeutics (Nasdaq: SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive. Sage developed the only two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. Sage was founded in 2010 and is headquartered in Cambridge, Mass.